Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia

Clinical Biochemistry

Volumn 47, Issue 1-2, 2014, Pages 8-15

  Martins, Telma ^a   Vitorino, Rui ^a   Moreira Gonçalves, Daniel ^b   Amado, Francisco ^a   Duarte, José Alberto ^b   Ferreira, Rita ^a  

^a UNIVERSITY OF AVEIRO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Cardiac cachexia; Chronic heart failure; Heart failure; Mechanisms

Indexed keywords

ADRENALIN; ANABOLIC AGENT; APPETITE STIMULANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ETANERCEPT; FORMOTEROL; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LOOP DIURETIC AGENT; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METOPROLOL; MYOSTATIN; NEBIVOLOL; NEUROHORMONE; NORADRENALIN; PENTOXIFYLLINE; PROCOAGULANT; PROTEASOME INHIBITOR; THALIDOMIDE; THIAZIDE DIURETIC AGENT; TRANSCRIPTION FACTOR FOXO; UNINDEXED DRUG;

ADRENERGIC SYSTEM; ANTIINFLAMMATORY ACTIVITY; APPETITE; AUTOIMMUNE DISEASE; CACHEXIA; CARDIAC CACHEXIA; CARDIOVASCULAR DISEASE; CIRCULATION; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENERGY EXPENDITURE; EXERCISE; HEART FAILURE; HEART MUSCLE; HEART PROTECTION; HORMONE RELEASE; HUMAN; IMMUNOADSORPTION; INSULIN RESISTANCE; LIPOLYSIS; MARASMUS; METABOLIC ACTIVATION; MUSCLE ATROPHY; MUSCLE DISEASE; NEUROENDOCRINE DISEASE; NONHUMAN; NUTRITION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PUBLIC HEALTH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTING ENERGY EXPENDITURE; REVIEW; SKELETAL MUSCLE; UBIQUITINATION; VASCULAR ENDOTHELIUM; WEIGHT REDUCTION;

4E-BP1; ACE; ANGIOTENSIN-CONVERTING ENZYME; ANP; ATRIAL NATRIURETIC PEPTIDE; BMD; BMI; BNP; BODY MASS INDEX; BONE MINERAL DENSITY; BRAIN NATRIURETIC PEPTIDE; CARDIAC CACHEXIA; CC; CHF; CHRONIC HEART FAILURE; CNOS; COMPUTED TOMOGRAPHY; CONSTITUTIVE NITRIC OXIDE SYNTHASE; CT; DEHYDROEPIANDROSTERONE; DHEA; EIF-4E; ERYTHROCYTE SEDIMENTATION RATE; ESR; EUKARYOTIC TRANSLATION INITIATION FACTOR 4E BINDING PROTEIN; FORKHEAD BOX O; FOXO; GC; GFR; GH; GLOMERULAR FILTRATION RATE; GLUCOCORTICOIDS; GROWTH HORMONE; HEART FAILURE; HF; IGF; IGFBP-3; IGFBPS; IL-1; IL-10; IL-1Β; IL-6; INHIBITOR OF THE EUKARYOTIC TRANSLATION INITIATION FACTOR 4E; INSULIN-LIKE GROWTH FACTOR; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INTERLEUKIN 1; INTERLEUKIN 1 BETA; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LPS; MAGNETIC RESONANCE IMAGING; MECHANISMS; MRI; N-TERMINAL PRO-BNP; NATRIURETIC PEPTIDE SYSTEM; NITRIC OXIDE SYNTHASE; NOS; NPS; NT-PROBNP; P70 RIBOSOMAL PROTEIN S6 KINASE 1; P70S6K1; PARASYMPATHETIC NERVOUS SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASE; PI3K; PLASMA RENIN ACTIVITY; PNS; PRA; RAAS; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM; ROS; SNS; SOLUBLE FORM OF TUMOR NECROSIS FACTOR RECEPTOR; STNFR; SYMPATHETIC NERVOUS SYSTEM; TGF-Β1; TNF-Α; TNFRS; TRANSFORMING GROWTH FACTOR BETA 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS GROWTH FACTOR RECEPTORS; UBIQUITIN-PROTEASOME PATHWAY; UPP;

BIOLOGICAL MARKERS; CACHEXIA; HEART FAILURE; HUMANS;

EID: 84890549464     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.10.025     Document Type: Review

References (77)

1. Steinborn W., Anker S.D. Cardiac cachexia: pathophysiology and clinical implications. Basic Appl Myology 2003, 13:191-201.
2. Lam L., Lind J., Semsarian C. Application of proteomics in cardiovascular medicine. Int J Cardiol 2006, 108:12-19.
3. Anker S.D., von Haehling S. Inflammatory mediators in chronic heart failure: An overview. Heart 2004, 90:464-470.
4. von Haehling S., Jankowska E., Anker S. Tumour necrosis factor-α and the failing heart: Pathophysiology and therapeutic implications. Basic Res Cardiol 2004, 99:18-28.
5. von Haehling S., Doehner W., Anker S.D. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 2007, 73:298-309.
6. Jankowska E.A., Ponikowski P., Piepoli M.F., Banasiak W., Anker S.D., Poole-Wilson P.A. Autonomic imbalance and immune activation in chronic heart failure-pathophysiological links. Cardiovasc Res 2006, 70:434-445.
7. Weber K.T., Gerling I.C., Kiani M.F., Guntaka R.V., Sun Y., Ahokas R.A., et al. Aldosteronism in heart failure: A proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets 2003, 4:505-516.
8. Anker S.D. Imbalance of catabolic and anabolic pathways in chronic heart failure: Implications for the treatment of cardiac cachexia. Scand J Nutr 2002, 46:3-10.
9. Sharma R., Anker S.D. Immune and neurohormonal pathways in chronic heart failure. Congestive Heart Fail 2002, 8:23-48.
10. Schulze P.C., Späte U. Insulin-like growth factor-1 and muscle wasting in chronic heart failure. Int J Biochem Cell Biol 2005, 37:2023-2035.
11. Yndestad A., Kristian Damås J., Øie E., Ueland T., Gullestad L., Aukrust P. Systemic inflammation in heart failure-the whys and wherefores. Heart Fail Rev 2006, 11:83-92.
12. Sharma R., Coats A.J.S., Anker S.D. The role of inflammatory mediators in chronic heart failure: Cytokines, nitric oxide, and endothelin-1. Int J Cardiol 2000, 72:175-186.
13. Anker S.D., Coats A.J.S. Cardiac cachexia*a syndrome with impaired survival and immune and neuroendocrine activation. Chest J 1999, 115:836-847.
14. Akashi Y., Springer J., Anker S. Cachexia in chronic heart failure: Prognostic implications and novel therapeutic approaches. Curr Heart Fail Rep 2005, 2:198-203.
15. von Haehling S., Lainscak M., Springer J., Anker S.D. Cardiac cachexia: A systematic overview. Pharmacol Ther 2009, 121:227-252.
16. Anker S.D., Sharma R. The syndrome of cardiac cachexia. Int J Cardiol 2002, 85:51-66.
17. Strassburg S., Springer J., Anker S.D. Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol 2005, 37:1938-1947.
18. Rydén M., Arner P. Fat loss in cachexia-is there a role for adipocyte lipolysis?. Clin Nutr 2007, 26:1-6.
19. Anker S.D., Ponikowski P.P., Clark A.L., Leyva F., Rauchhaus M., Kemp M., et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999, 20:683-693.
20. Cavey J. Cardiac cachexia. J Nurse Pract 2011, 7:578-581.
21. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236-241.
22. McMurray J., Abdullah I., Dargie H.J., Shapiro D. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J 1991, 66:356-358.
23. Testa M., Yeh M., Lee P., Berman J.W., Lejemtel T.H., Fanelli R., et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996, 28:964-971.
24. Tsutamoto T., Hisanaga T., Wada A., Maeda K., Ohnishi M., Fukai D., et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998, 31:391-398.
25. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (solvd). J Am Coll Cardiol 1996, 27:1201-1206.
26. Aukrust P., Ueland T., Lien E., Bendtzen K., Müller F., Andreassen A.K., et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999, 83:376-382.
27. Torre-Amione G., Kapadia S., Lee J., Durand J.-B., Bies R.D., Young J.B., et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93:704-711.
28. Tsutamoto T., Wada A., Ohnishi M., Tsutsui T., Ishii C., Ohno K., et al. Transcardiac increase in tumor necrosis factor-α and left ventricular end-diastolic volume in patients with dilated cardiomyopathy. Eur J Heart Fail 2004, 6:173-180.
29. Skipworth R.J.E., Stewart G.D., Ross J.A., Guttridge D.C., Fearon K.C.H. The molecular mechanisms of skeletal muscle wasting: Implications for therapy. Surgeon 2006, 4:273-283.
30. Hasselgren P.-O., Fischer J.E. Muscle cachexia: Current concepts of intracellular mechanisms and molecular regulation. Ann Surg 2001, 233:9-17.
31. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 2002, 82:373-428.
32. Varshavsky A. The n-end rule pathway of protein degradation. Genes Cells 1997, 2:13-28.
33. Solomon V., Baracos V., Sarraf P., Goldberg A.L. Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the n-end rule pathway. Proc Natl Acad Sci 1998, 95:12602-12607.
34. Saini A., Nasser A.-S., Stewart C.E.H. Waste management-cytokines, growth factors and cachexia. Cytokine Growth Factor Rev 2006, 17:475-486.
35. Loncar G., Fülster S., von Haehling S., Popovic V. Metabolism and the heart: An overview of muscle, fat, and bone metabolism in heart failure. Int J Cardiol 2013, 162:77-85.7.
36. Francis S.E., Holden H., Holt C.M., Duff G.W. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1998, 30:215-223.
37. Gulick T., Chung M.K., Pieper S.J., Lange L.G., Schreiner G.F. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte ß-adrenergic responsiveness. Proc Natl Acad Sci U S A 1989, 86:6754-6757.
38. Grunfeld C., Zhao C., Fuller J., Pollock A., Moser A., Friedman J., et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters: A role for leptin in the anorexia of infection. J Clin Invest 1996, 97:2152-2157.
39. Gayle D., Ilyin S.E., Plata-Salamán C.R. Central nervous system il-1β system and neuropeptide y mrnas during il-1β-induced anorexia in rats. Brain Res Bull 1997, 44:311-317.
40. Packer M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992, 20:248-254.
41. Ferrara R., Mastrorilli F., Pasanisi G., Censi S., D'aiello N., Fucili A., et al. Neurohormonal modulation in chronic heart failure. Eur Heart J Suppl 2002, 4:D3-D11.
42. Abassi Z., Karram T., Ellaham S., Winaver J., Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: Diagnostic and therapeutic importance. Pharmacol Ther 2004, 102:223-241.
43. Brink M., Anwar A., Delafontaine P. Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia. Int J Cardiol 2002, 85:111-121.
44. Schakman O., Gilson H., Thissen J.P. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008, 197:1-10.
45. Gullestad L., Aukrust P., Ueland T., Espevik T., Yee G., Vagelos R., et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999, 34:2061-2067.
46. Packer M., Coats A.J.S., Fowler M.B., Katus H.A., Krum H., Mohacsi P., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
47. Argilés J.M., López-Soriano F.J., Busquets S. Novel approaches to the treatment of cachexia. Drug Discov Today 2008, 13:73-78.
48. McCarthy H.D., Crowder R.E., Dryden S., Williams G. Megestrol acetate stimulates food and water intake in the rat: Effects on regional hypothalamic neuropeptide y concentrations. Eur J Pharmacol 1994, 265:99-102.
49. Mantovani G., Macciò A., Massa E., Madeddu C. Managing cancer-related anorexia/cachexia. Drugs 2001, 61:499-514.
50. Costa A.M., Spence K.T., Plata-Salamán C.R. ffrench-Mullen JM. Residual ca2+ channel current modulation by megestrol acetate via a g-protein alpha s-subunit in rat hypothalamic neurones. J Physiol 1995, 487:291-303.
51. Srivastava M.D., Srivastava B.I.S., Brouhard B. δ9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998, 40:179-185.
52. Watzl B., Scuderi P., Watson R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol 1991, 13:1091-1097.
53. Sato Y., Fujiwara H., Takatsu Y. Biochemical markers in heart failure. J Cardiol 2012, 59:1-7.
54. Richards A.M. New biomarkers in heart failure: Applications in diagnosis, prognosis and guidance of therapy. Rev Esp Cardiol 2010, 63.
55. Members A.T.F., Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J.V., Ponikowski P., et al. Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. Developed in collaboration with the heart failure association of the esc (hfa) and endorsed by the european society of intensive care medicine (esicm). Eur Heart J 2008, 29:2388-2442.
56. Emdin M., Vittorini S., Passino C., Clerico A. Old and new biomarkers of heart failure. Eur J Heart Fail 2009, 11:331-335.
57. Palazzuoli A., Caputo M., Calabrò A., R N Clinical impact of bnp and other emerging biomarkers in heart failure evaluation and management. Minerva Cardioangiol 2012, 60:183-194.
58. Lainscak M., von Haehling S., Anker S.D. Natriuretic peptides and other biomarkers in chronic heart failure: From bnp, nt-probnp, and mr-proanp to routine biochemical markers. Int J Cardiol 2009, 132:303-311.
59. Lee D., Vasan R.S. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 2005, 20:201-210.
60. Gerszten R.E., Wang T.J. The search for new cardiovascular biomarkers. Nature 2008, 451:949-952.
61. Rocchiccioli J., McMurray J., Dominiczak A. Biomarkers in heart failure: A clinical review. Heart Fail Rev 2010, 15:251-273.
62. Nagaya N., Uematsu M., Kojima M., Date Y., Nakazato M., Okumura H., et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure. Circulation 2001, 104:2034-2038.
63. Nishikimi T., Saito Y., Kitamura K., Ishimitsu T., Eto T., Kangawa K., et al. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 1995, 26:1424-1431.
64. Moriyama Y., Yasue H., Yoshimura M., Mizuno Y., Nishiyama K., Tsunoda R., et al. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab 2000, 85:1834-1840.
65. Kawano H., Nagayoshi Y., Soejima H., Tanaka Y., Yamabe H., Kinoshita Y., et al. Dehydroepiandrosterone levels vary according as heart failure condition in patients with idiopathic dilated cardiomyopathy. Int J Cardiol 2008, 125:277-279.
66. Pousset F., Isnard R., Lechat P., Kalotka H., Carayon A., Maistre G., et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997, 18:254-258.
67. Anker S.D., Chua T.P., Ponikowski P., Harrington D., Swan J.W., Kox W.J., et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997, 96:526-534.
68. Roig E., Perez-Villa F., Morales M., Jiménez W., Orús J., Heras M., et al. Clinical implications of increased plasma angiotensin ii despite ace inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000, 21:53-57.
69. Güder G., Bauersachs J., Frantz S., Weismann D., Allolio B., Ertl G., et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007, 115:1754-1761.
70. Tsutamoto T., Hisanaga T., Fukai D., Wada A., Maeda Y., Maeda K., et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 1995, 76:803-808.
71. Anker S.D., Volterrani M., Pflaum C.-D., Strasburger C.J., Osterziel K.J., Doehner W., et al. Acquired growth hormone resistance in patients with chronic heart failure: Implications for therapy with growth hormone. J Am Coll Cardiol 2001, 38:443-452.
72. Carlstedt F., Lind L., Lindahl B. Proinflammatory cytokines, measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease. J Intern Med 1997, 242:361-365.
73. Keith M., Geranmayegan A., Sole M.J., Kurian R., Robinson A., Omran A.S., et al. Increased oxidative stress in patients with congestive heart failure 1. J Am Coll Cardiol 1998, 31:1352-1356.
74. Haber H.L., Leavy J.A., Kessler P.D., Kukin M.L., Gottlieb S.S., Packer M. The erythrocyte sedimentation rate in congestive heart failure. N Engl J Med 1991, 324:353-358.
75. Sharma R., Rauchhaus M., Ponikowski P.P., Varney S., Poole-Wilson P.A., Mann D.L., et al. The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2000, 36:523-528.
76. Anker S.D., Doehner W., Rauchhaus M., Sharma R., Francis D., Knosalla C., et al. Uric acid and survival in chronic heart failure. Circulation 2003, 107:1991-1997.
77. Doehner W., Rauchhaus M., Florea V.G., Sharma R., Bolger A.P., Davos C.H., et al. Uric acid in cachectic and noncachectic patients with chronic heart failure: Relationship to leg vascular resistance. Am Heart J 2001, 141:792-799.